ArticleBiomedical engineering online2025
Conditioned media and extracellular vesicles derived from human Wharton's jelly mesenchymal stem cells improve the in vitro maturation of immature oocytes in normal and PCOS mouse model.
Article in Biomedical engineering online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Gene Function to Precision Intervention: CRISPR/Cas9 and Stem Cell-Based Strategies as Emerging Disease-Modifying Approaches in PMOS.Stem cell reviews and reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effects of conditioned medium (CM) and extracellular vesicles (EVs) derived from human Wharton's jelly mesenchymal stem cells (hWJMSCs) on in vitro maturation (IVM) of immature oocytes in both normal and polycystic ovary syndrome (PCOS)-induced mice were investigated. PCOS was induced in adult female NMRI mice by administering letrozole (90 μg/kg/day) via gavage for one week. Germinal vesicle (GV) oocytes were collected from both PCOS-induced and normal mice, while mature oocytes (MII) were obtained from superovulated normal mice to serve as controls. The experimental groups included 7 groups: Control (MII oocytes), 3 IVM groups (in vitro maturation of GV oocytes): IVM (with simple IVM media), IVM + CM, and IVM + EVs (IVM media supplemented with CM and EVs, respectively), and three PCOS groups (in vitro maturation of GV oocytes from PCOS-induced mice): PCOS IVM (with simple IVM media), PCOS IVM + CM, and PCOS IVM + EVs (IVM media supplemented with CM and EVs, respectively). After IVM was conducted in all groups, mature oocytes were harvested and assessed for maturation rate, morphology, viability, and gene expression profiles of key regulators (CDK1, CCNB1, MAP2K). Developmentally competent oocytes were selected using Brilliant Cresyl Blue staining and then subjected to in vitro maturation with or without CM or EVs supplementation. Nuclear maturation was evaluated via orcein staining, while viability was assessed using Trypan Blue. Morphometric parameters were measured using ImageJ software. Real-time PCR was utilized for the evaluation of gene expression of targeted genes.
resultsResults demonstrated that in BCB + oocytes, CM and EVs improved the mature oocytes compared to IVM. Oocytes from PCOS-induced mice exhibited reduced maturation and increased degeneration, which were rescued by CM and EV treatment. Gene expression analysis revealed downregulation of MAP2K, CCNB1, and CDK1 in IVM and PCOS IVM groups compared to the control group, while CM supplementation restored their expression. Oocyte diameter and viability were significantly enhanced in IVM + CM compared to IVM (P < 0.05).
conclusionsThese findings suggest that hWJMSC-derived secretomes, particularly CM, enhance oocyte maturation and quality, offering potential therapeutic benefits for IVM in both normal and PCOS conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.